梁澄宇醫生 - 內科腫瘤科
內科腫瘤科專科醫生
重點資料
- 醫務委員會註冊已驗證
- 內科腫瘤科專科醫生愛丁堡大學內外全科醫學士 · 1997 年醫科畢業
- 保險計劃資料整理中｜查看詳情
關於醫生
梁澄宇醫生是香港註冊的內科腫瘤科專科醫生。
學歷
內科腫瘤科專科醫生
- 愛丁堡大學內外全科醫學士1997
保險計劃
常見問題
梁澄宇醫生好嗎？
梁澄宇醫生是香港註冊的內科腫瘤科專科醫生。資歷及註冊資料來自香港醫務委員會。ok.med 不評分，也不排名。
梁澄宇醫生是做什麼的？
梁澄宇醫生是內科腫瘤科醫生。
研究及論文
共 25 篇，顯示最近 12 篇
按論文主題篩選
主題由同一批 PubMed 論文的醫學分類整理，不代表醫生提供相關診治服務。
- Efficacy and Safety of Neoadjuvant Dual HER2-Targeted Therapy in Older and Younger Patients With HER2-Positive Early Breast Cancer: A Real-World Retrospective Analysis.Clinical breast cancer · 2026
- Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.Frontiers in oncology · 2026
- Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study.Advances in therapy · 2025
- Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma.Biomedicines · 2025
- A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.Investigational new drugs · 2025
- A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial.Translational gastroenterology and hepatology · 2025
- Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.Oncology and therapy · 2024
- Consensus Statements on Precision Oncology in the China Greater Bay Area.JCO precision oncology · 2023
- Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?Hepatology communications · 2023
- Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2021
- Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.Cancers · 2021
- Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.Expert review of gastroenterology & hepatology · 2021
論文資料來自 PubMed／Europe PMC，按姓名及機構自動配對；每項均可按連結核對。
網上資料
以上連結按醫生姓名自動配對，未經醫生本人確認。香港同名者不少，請按連結自行核對。
僅供參考，不構成醫療建議。 閱讀完整免責聲明